fda warning letters compounded semaglutide tirzepatide september 2025 15, 2025: Telehealth company must stop implying its GLP-1 is FDA-approved, warns – Partnership for Safe Medicines A company called Nomida has
Description
so nice
Direct-to-patient distribution models like this are likely to evolve beyond GLP-1s to include other medication categories like migraine therapies and womens/mens health, CenterWells Sollberger said
Theyre uncomfortable and can dissuade people from continuing to use them
Tirzepatide: Tirzepatide combines the effects of two hormonesGLP-1 and glucose-dependent insulinotropic polypeptide (GIP)
Oral incretin therapy is moving into the mainstream, potentially lowering barriers and enabling earlier, wider adoption in obesity care
The liveralpha-cell axis in health and in disease
